Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 6, 2026 (Event Date); March 9, 2026 (Signature Date)
Context: The filing discloses regulatory milestones regarding the Company's lead candidate, lorundrostat, including FDA acceptance of a New Drug Application (NDA) and topline results from a Phase 2 exploratory trial.
Key Financial Metrics
This Form 8-K is a current report focused on regulatory and clinical events. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Results
FDA Regulatory Status
- NDA Acceptance: On March 6, 2026, the FDA accepted the NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.
- Target Action Date: The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
Phase 2 Explore-OSA Trial Results
- Study Design: Exploratory Phase 2 trial with 48 participants (Average BMI: 38.2 kg/m²; Average AHI: 48.5 events/hr; Average Systolic BP: 142.3 mmHg).
- Primary Endpoint (AHI): Lorundrostat 50 mg (evening dose) did not demonstrate a clinically meaningful difference relative to placebo on the Apnea-Hypopnea Index (AHI) after four weeks.
- Blood Pressure Reduction:
- Parallel Arm Analysis: 11.1 mmHg reduction with lorundrostat vs. 1.0 mmHg with placebo (p < 0.0001).
- Crossover Analysis: 6.2 mmHg placebo-adjusted reduction (p < 0.0003).
- Safety: Favorable safety profile; well tolerated with no serum potassium excursions above 5.5 mmol/L.
Outlook, Risks, and Management Commentary
- Future Reporting: Analysis for other endpoints in the Explore-OSA trial is ongoing and will be reported in future publications or medical meetings.
- Regulatory Path: The Company is now awaiting the FDA's decision by the December 22, 2026 target action date for the hypertension indication.
- Risk Note: The failure to meet the primary endpoint in the OSA exploratory trial indicates the drug may not be effective for sleep apnea, though it showed efficacy in lowering blood pressure.
Investor Verification Checklist
- Verify the specific PDUFA target action date of December 22, 2026, for the hypertension NDA.
- Review the full press release (Exhibit 99.1) for detailed statistical data on the Explore-OSA trial.
- Monitor future announcements regarding the analysis of secondary endpoints in the Explore-OSA trial.
- Assess the impact of the negative primary endpoint in the OSA trial on the Company's overall pipeline valuation and potential indications.